Forte Biosciences (FBRX) Preferred Stock Liabilities (2016 - 2020)

Forte Biosciences (FBRX) has 5 years of Preferred Stock Liabilities data on file, last reported at $10.5 million in Q1 2020.

• Preferred Stock Liabilities for Q1 2020 came in at $10.5 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2020 was $10.5 million (changed 0.0% YoY), and the FY2019 annual result was $10.5 million, up 85.81% from the prior year.
• Preferred Stock Liabilities held at $10.5 million in Q1 2020 per FBRX's latest filing, from $10.5 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $10.5 million in Q1 2019 and troughed at $67000.0 in Q1 2017.
• A 5-year average of $7.3 million and a median of $10.5 million in 2019 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2019 and 2020: Preferred Stock Liabilities surged 85.81% in 2019, then changed 0.0% in 2020.
• A 5-year view of Preferred Stock Liabilities shows it stood at $126000.0 in 2016, then plunged by 46.83% to $67000.0 in 2017, then jumped by 8346.27% to $5.7 million in 2018, then surged by 85.81% to $10.5 million in 2019, then changed by 0.0% to $10.5 million in 2020.
• Business Quant data shows FBRX's Preferred Stock Liabilities at $10.5 million in Q1 2020, $10.5 million in Q4 2019, and $10.5 million in Q3 2019.